Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

PCYT1A in MYC-Driven Lymphoma: Role on Aberrant Choline Metabolism and Therapeutic Targeting By Berberine

Jie Xiong, PhD, Li Wang, MDPhD, Weili Zhao, MDPhD

Blood (2015) 126 (23): 698.

https://doi.org/10.1182/blood.V126.23.698.698

Published: 2015

Journal Articles

Availability of Circulating microRNAs As a Biomarker for the Early Diagnosis of Diffuse Large B-Cell Lymphoma

Katsushige Inada, PhD, Yasushi Okoshi, MD PhD, Yukiko Cho, PhD, Hitoaki Saito, MD PhD, Tatsuo Iijima, MD PhD, Mitsuo Hori, MD PhD, Hiroshi Kojima, MD PhD

Blood (2014) 124 (21): 2988.

https://doi.org/10.1182/blood.V124.21.2988.2988

Published: 2014

Journal Articles

Lost in Post-Translation, Found by Mass Spectrometry: Identification of Novel Biomarkers and Biologic Insights in Lymphoma Pathogenesis

Kojo S.J. Elenitoba-Johnson, MD

Blood (2013) 122 (21): SCI-23.

https://doi.org/10.1182/blood.V122.21.SCI-23.SCI-23

Published: 2013

Journal Articles

Chronic Lymphocytic Leukemia-Derived Exosomes Stimulate Cells From The Microenvironment

Jerome Paggetti, PhD, Guy J. Berchem, MD, Etienne Moussay, PhD

Blood (2013) 122 (21): 3683.

https://doi.org/10.1182/blood.V122.21.3683.3683

Published: 2013

Journal Articles

Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456)

Bertrand Coiffier, MD, PhD, Catherine Thieblemont, MD, PhD, Sophie de Guibert, MD, Jehan Dupuis, MD, Vincent Ribrag, Réda Bouabdallah, MD, Franck Morschhauser, MD, PhD, Guillaume Cartron, MD, PhD, Steven Le Gouill, MD, PhD, Olivier Casasnovas, MD, Harald Holte, MD, PhD, Laurence Hatteville, Chiara Zilocchi, Corina Oprea, MD, Hervé Tilly, MD, PhD

Blood (2013) 122 (21): 4395.

https://doi.org/10.1182/blood.V122.21.4395.4395

Published: 2013

Journal Articles

Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma

Minna Taskinen, PhD, Ping Chen, MSc, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Alejandra Cervera, MSc, Jan Delabie, Harald Holte, MD, PhD, Sampsa Hautaniemi, Sirpa Leppä

Blood (2013) 122 (21): 75.

https://doi.org/10.1182/blood.V122.21.75.75

Published: 2013

Journal Articles

Plasma Level of Micro-RNA92-a in Acute Myeloidleukemia and Its Correlation with Prognostic Factors and Therapeutic Response

Ahmed Galal, MD, MSc, FRCPC

Blood (2012) 120 (21): 4826.

https://doi.org/10.1182/blood.V120.21.4826.4826

Published: 2012

Journal Articles

MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study

Sarit Assouline, MD, Julie Chang, MD, Robert Rifkin, MD, Ai-Min Hui, MD, Deborah Berg, RN, MSN, Neeraj Gupta, PhD, Yingmei Xi, PhD, Alessandra Di Bacco, PhD, Peter Martin, MD

Blood (2011) 118 (21): 2672.

https://doi.org/10.1182/blood.V118.21.2672.2672

Published: 2011

Journal Articles

Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,

Michael J. Robertson, MD, John Bauman, Olivia Gardner, Zdenka Jonak, Herbert Struemper, Fiona Germaschewski, Kevin M. Koch, Sharon Murray, Jill Weisenbach, RN, John Toso, MD, MSc

Blood (2011) 118 (21): 3697.

https://doi.org/10.1182/blood.V118.21.3697.3697

Published: 2011

Journal Articles

Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu

Bani M Azari, MD/PhD, Danielle F Joseph, PhD, Marc J Braunstein, MD/PhD, H. Uwe Klueppelberg, MD, Eric LP Smith, PhD, Sadeaqua Scott, PhD, Jonathan D Marmur, MD, Anna Babinska, PhD, Olcay Batuman, MD

Blood (2010) 116 (21): 450.

https://doi.org/10.1182/blood.V116.21.450.450

Published: 2010

Journal Articles

Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.

Blood (2009) 114 (22): 1713.

https://doi.org/10.1182/blood.V114.22.1713.1713

Published: 2009

Journal Articles

Diagnostic Plasma-Derived Proteomic Biomarkers of Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075 French GEOLAMS Multicentric and Prospective Trial.

Delphine Maucort-Boulch, Marie Arlotto, Delphine Rossille, Céline Pangault, Pascal Roy, François Berger, Anita Burgun, Marie-Christine Béné, Thierry Lamy, Noel-Jean Milpied, Thierry Fest

Blood (2009) 114 (22): 2933.

https://doi.org/10.1182/blood.V114.22.2933.2933

Published: 2009

Journal Articles

Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Disease-Relevant Pathways and Overlaps with Common Cancer Biomarkers

Marc J. Braunstein, Fabien Campagne, PhD, Piali Mukherjee, Daniel Ruben Carrasco, M.D., Ph.D., Kumar Sukhdeo, Alexei Protopopov, Kenneth C Anderson, MD, Olcay Batuman, MD

Blood (2008) 112 (11): 626.

https://doi.org/10.1182/blood.V112.11.626.626

Published: 2008

Journal Articles

Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Overlaps with Myeloma Tumor Cells and Common Cancer Gene-Pathways.

Marc J. Braunstein, Daniel R. Carrasco, Fabien Campagne, Piali Mukherjee, Kumar Sukhdeo, Alexei Protopopov, Kenneth C. Anderson, Olcay A. Batuman

Blood (2007) 110 (11): 394.

https://doi.org/10.1182/blood.V110.11.394.394

Published: 2007

NARROW

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

PCYT1A in MYC-Driven Lymphoma: Role on Aberrant Choline Metabolism and Therapeutic Targeting By Berberine

Availability of Circulating microRNAs As a Biomarker for the Early Diagnosis of Diffuse Large B-Cell Lymphoma

Lost in Post-Translation, Found by Mass Spectrometry: Identification of Novel Biomarkers and Biologic Insights in Lymphoma Pathogenesis

Chronic Lymphocytic Leukemia-Derived Exosomes Stimulate Cells From The Microenvironment

Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456)

Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma

Plasma Level of Micro-RNA92-a in Acute Myeloidleukemia and Its Correlation with Prognostic Factors and Therapeutic Response

MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study

Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,

Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu

Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.

Diagnostic Plasma-Derived Proteomic Biomarkers of Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075 French GEOLAMS Multicentric and Prospective Trial.

Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Disease-Relevant Pathways and Overlaps with Common Cancer Biomarkers

Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Overlaps with Myeloma Tumor Cells and Common Cancer Gene-Pathways.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only